Disease · HP_0010992
Targets19
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 19 of 19
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | 5 | Norepinephrine transporter inhibitor | Approval | https://conductscience.org/library/genes/6530 | Drugs and targets |
| AR | Androgen receptor | 3 | Androgen Receptor agonist; Androgen Receptor modulator | Phase 2 | https://conductscience.org/library/genes/367 | Drugs and targets |
| SLC6A4 | Sodium-dependent serotonin transporter | 3 | Serotonin transporter inhibitor | Approval | https://conductscience.org/library/genes/6532 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 3 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| CHRM2 | Muscarinic acetylcholine receptor M2 | 1 | Muscarinic acetylcholine receptor M2 antagonist | Phase 2 | https://conductscience.org/library/genes/1129 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 1 | Muscarinic acetylcholine receptor M3 antagonist | Phase 2 | https://conductscience.org/library/genes/1131 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor modulator | Phase 3 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| ESR2 | Estrogen receptor | 1 | Estrogen receptor modulator | Phase 3 | https://conductscience.org/library/genes/2100 | Drugs and targets |
| P2RX3 | P2X purinoceptor 3 | 1 | P2X purinoceptor 3 antagonist | Phase 3 | https://conductscience.org/library/genes/5024 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6332 | Drugs and targets |
| SCN8A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6334 | Drugs and targets |
| SCN9A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6335 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0010992/targets